Rocket One Inc.
Rocket One Inc. is a U.S.-based pharmaceutical preparations company focused on pre-clinical and clinical development of product candidates. The company operates as a development-stage biopharmaceutical business and has not yet commercialized any products.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2020–2025
Liiketoiminta
Osuus liikevaihdostaResearch, testing, and advancement of drug candidates through pre-clinical and clinical stages.
License, sublicense, sponsored research, and option agreements tied to pipeline development.
Asiakkaat
Rocket One's direct counterparties are primarily licensing partners, research collaborators, and other third parties involved in its development agreements. Its eventual end customers would be patients and healthcare providers, but the company is still in the product-development stage and has not generated product sales. The business model depends on external capital and strategic counterparties rather than a broad commercial customer base.
Third parties that enter license, sublicense, sponsored research, and option agreements to access pipeline assets or share development economics.
Equity and debt investors that fund ongoing R&D and working capital needs while the company remains pre-revenue.
Patients, physicians, and healthcare systems that would use approved products if development succeeds.
Strategia
The company’s strategy is centered on advancing pre-clinical and clinical product candidates while securing the capital needed to fund development. It also relies on licensing and collaboration structures to support pipeline progress and future commercialization options. Success depends on converting research assets into fundable programs and, eventually, revenue-generating products.
Development-stage biopharma requires external funding before product revenue exists.
Clinical and pre-clinical progress is the main driver of future value creation.
Long-term value depends on moving from development to approved, marketable therapies.
Maantiede
Rocket One is headquartered in the United States and its reported disclosures are U.S.-centric. The company’s development, financing, and regulatory exposure are tied mainly to the U.S. healthcare and capital markets environment. No authoritative revenue geography breakdown was provided, and the company has not yet commercialized products.
Riskit
Rocket One faces the classic risks of a development-stage biopharmaceutical company: it may never successfully advance product candidates to commercialization, and it depends on outside capital to continue operations. The company also has exposure to digital-asset-related market and custody risks disclosed in its filings, alongside ordinary biotech risks such as clinical failure, regulatory delay, and partner dependence.
- Funding shortfallVaikutus: KorkeaTodennäköisyys: Kohtalainen
The company states it will need additional capital to fund R&D and obligations.
Kohdistuu - Clinical and development failureVaikutus: KorkeaTodennäköisyys: Matala
Pre-clinical and clinical assets may not achieve required safety or efficacy outcomes.
Kohdistuu: Pipeline value and future commercialization prospects
- Digital asset custody and cyber riskVaikutus: KeskitasoTodennäköisyys: Matala
The company disclosed that digital assets are held at Coinbase and are exposed to breaches.
Kohdistuu: Potential loss of digital assets and reputational harm
- Healthcare reimbursement and regulatory pressureVaikutus: KeskitasoTodennäköisyys: Matala
Drug commercialization depends on approval, pricing, and reimbursement conditions.
Kohdistuu: Future market access and revenue realization
- Partner and milestone obligationsVaikutus: Keskitaso
License and research agreements may require maintenance fees, royalties, and milestones.
Kohdistuu: Cash outflows and contractual dependence on third parties
Kirjanpito
Harkinnanvaraiset erätThe company values option awards using Black-Scholes assumptions that affect reported expense.
Vaikutus: Can materially change general and administrative and R&D expense
Management states the company may not have sufficient cash to fund operations for 12 months.
Vaikutus: Affects financial statement presentation and investor assessment of solvency
Agreements may require milestone, royalty, and maintenance payments if development advances.
Vaikutus: Potential future liabilities and cash outflows
Digital assets held at Coinbase introduce custody, impairment, and disclosure considerations.
Vaikutus: Can affect balance sheet presentation and risk disclosures
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Rocket Pharmaceuticals, Inc
RCKT · Pharmaceutical Preparations
Rocket Pharmaceuticals is a U.S.-based late-stage biotechnology company focused on developing genetic therapies for rare inherited diseases.
Day One Biopharmaceuticals, Inc.
Pharmaceutical Preparations
Day One Biopharmaceuticals is a U.S.-based commercial-stage biopharmaceutical company focused on targeted therapies for childhood and adult cancers.
Replimune Group, Inc.
REPL · Biological Products, (No Diagnostic Substances)
Shuttle Pharmaceuticals Holdings, Inc.
SHPH · Pharmaceutical Preparations
RAPT Therapeutics, Inc.
Pharmaceutical Preparations
Rocket Companies, Inc.
RKT · Mortgage Bankers & Loan Correspondents
Päivitetty: 24.9.2026